| (84) |
Designated Contracting States: |
|
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO SE SI SK SM TR |
| (30) |
Priority: |
10.12.2008 US 121220 P
|
| (43) |
Date of publication of application: |
|
17.08.2011 Bulletin 2011/33 |
| (60) |
Divisional application: |
|
17174362.8 |
| (73) |
Proprietor: The Henry M. Jackson Foundation for the
Advancement of Military Medicine, Inc. |
|
Bethesda, MD 20817 (US) |
|
| (72) |
Inventors: |
|
- PEOPLES, George
San Antonio, TX 78209 (US)
- PONNIAH, Sathibalan
Columbia, MD 21044 (US)
|
| (74) |
Representative: Müller Fottner Steinecke |
|
Rechtsanwalts- und Patentanwaltspartnerschaft mbB
Postfach 31 01 40
80102 München
80102 München (DE) |
| (56) |
References cited: :
US-A- 5 550 214
US-B2- 7 211 432
|
US-A1- 2008 260 745
|
|
| |
|
|
- Peoples G E: "HER2/neu Vaccines for Cancer", , 16 November 2007 (2007-11-16), page
58PP, XP002691920, Retrieved from the Internet: URL:http://www.esmo.org/fileadmin/media/pr
esentations/826/LCT10001553.pdf [retrieved on 2013-02-07]
- Anonymous: "Selected Clinical Trials in Breast Cancer", Clinical Breast Cancer , 1
October 2007 (2007-10-01), pages 814-815, XP002691921, Retrieved from the Internet:
URL:http://cigjournals.metapress.com/conte nt/8438658656p493l0/fulltext.pdf [retrieved
on 2013-02-07]
- CARMICHAEL M ET AL: "Clinical results of a phase I trial of a HER2/neu-derived peptide
(GP2) vaccine in disease-free, node-negative breast cancer patients", BREAST CANCER
RESEARCH AND TREATMENT, vol. 106, no. Suppl. 1, 13 December 2007 (2007-12-13), - 16
December 2007 (2007-12-16), pages S30-S31, XP002691922, & 30TH ANNUAL SAN ANTONIO
BREAST CANCER SYMPOSIUM; SAN ANTONIO, TX, USA ISSN: 0167-6806
- MITTENDORF ET AL: "Vaccination with a HER2/neu peptide induces intra- and inter-antigenic
epitope spreading in patients with early stage breast cancer", SURGERY, vol. 139,
no. 3, 1 March 2006 (2006-03-01) , pages 407-418, XP005338910, C.V. MOSBY CO., ST.
LOUIS, US ISSN: 0039-6060, DOI: 10.1016/J.SURG.2005.06.059
- MITTENDORF ET AL: "HER-2/neu Peptide Breast Cancer Vaccines: Current Status and Future
Directions", BREAST DISEASES: A YEAR BOOK QUARTERLY, vol. 17, no. 4, 1 January 2007
(2007-01-01), pages 318-320, XP022090171, MOSBY, ST. LOUIS, MO, US ISSN: 1043-321X,
DOI: 10.1016/S1043-321X(07)80101-9
- ELIZABETH A MITTENDORF ET AL: "The E75 HER2/neu peptide vaccine", CANCER IMMUNOLOGY
IMMUNOTHERAPY, vol. 57, no. 10, 7 June 2008 (2008-06-07), pages 1511-1521, XP019624429,
SPRINGER, BERLIN, DE ISSN: 1432-0851
- ELIZABETH A MITTENDORF ET AL: "Evaluation of the HER2/neu-Derived Peptide GP2 for
Use in a Peptide-Based Breast Cancer Vaccine Trial", CANCER, vol. 106, 1 January 2006
(2006-01-01), pages 2309-2317, XP007910301, AMERICAN CANCER SOCIETY, PHILADELPHIA,
PA, US ISSN: 0008-543X, DOI: 10.1002/CNCR.21849
- HOLMES J P ET AL: "Intra-antigenic epitope spreading in HLA-A2+breast cancer patients
vaccinated with a MHC class I peptide (GP2) derived from the transmembrane region
of HER2/NEU", JOURNAL OF IMMUNOTHERAPY, vol. 30, no. 8, 4 November 2007 (2007-11-04),
page 896, XP009166967, LIPPINCOTT WILLIAMS & WILKINS, HAGERSTOWN, MD, US ISSN: 1524-9557
- MARK G. CARMICHAEL ET AL: "Results of the first phase 1 clinical trial of the HER-2/
neu peptide (GP2) vaccine in disease-free breast cancer patients", CANCER, vol. 116,
no. 2, 15 January 2010 (2010-01-15), pages 292-301, XP055140251, ISSN: 0008-543X,
DOI: 10.1002/cncr.24756
|
|
